Biogen Idec Inc (NASDAQ:BIIB)

Headlines for Biogen Idec Inc

HealthCor Urges Biogen Board Consider Number Of Changes
Wall Street Journal - Nov 20, 2009
By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--HealthCor Management, a hedge fund that owns a 1.3% stake in Biogen Idec Inc. (BIIB), sent a letter to the biotech's board criticizing ...
UPDATE 2-HealthCor slams Biogen CEO for outsize pay package - Reuters
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder - Xconomy
路透中国 - Mass High Tech - Bizjournals.com
Biogen's Rituxan Label Expansion Delayed
Zacks.com - Nov 20, 2009
Biogen Idec (BIIB - Analyst Report) and Genentech, Inc., a wholly-owned member of the Roche Group (RHHBY.PK), announced that they have received a complete response letter (CRL) from the US Food ...
Genentech & Biogen Idec get complete response letter from US FDA for Rituxan to treat CLL - pharmabiz.com
Market Report -- In Play (BIIB)
MSN Money - Nov 18, 2009
Biogen Idec and Genenech receive a complete response from the FDA for Rituxan for chronic lymphocytic leukemia Genentech, a wholly-owned member of the Roche, and BIIB announced that the FDA issued ...
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia - Earthtimes
Genentech and Biogen Idec obtain FDA complete response for leukemia drug - Trading Markets
RTT News - fox4kc.com - WTOP
www.bharatbook.com : Biogen Idec Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
PRMinds - Nov 18, 2009
www.bharatbook.com included a new report on "Biogen Idec Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" into its market report catalogue for reselling. Biogen Idec Inc. (Biogen ...
Activity Jumps in Biotech and Drug Firms
Wall Street Journal - Nov 18, 2009
By TENNILLE TRACY NEW YORK—Shares of Biogen Idec took a dive last month, after a European health agency launched a review of its multiple sclerosis drug, but some options traders appear to think ...